Результати пошуку - Jens Tijtgat

  • Показ 1 - 5 результатів із 5
Уточнити результати
  1. 1
    Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

    Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Pa... за авторством Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

    Опубліковано 2020-11-01
    Отримати повний текст
    Стаття
    Додати у Вибране
    Збережено в:
  2. 2
    Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells

    Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells за авторством Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L. Aerts, Bart Neyns, Sandra Tuyaerts

    Опубліковано 2021-10-01
    Отримати повний текст
    Стаття
    Додати у Вибране
    Збережено в:
  3. 3
    Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

    Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory adva... за авторством Bart Neyns, Angela Vasaturo, Julia Katharina Schwarze, Gil Awada, Ramses Forsyth, Jens Tijtgat, Louise Cras, Christopher Bagnall, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet

    Опубліковано 2022-09-01
    Отримати повний текст
    Стаття
    Додати у Вибране
    Збережено в:
  4. 4
    Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

    Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous... за авторством Bart Neyns, Julia Katharina Schwarze, Karen Willard-Gallo, Ramses Forsyth, Jens Tijtgat, Sandra Tuyaerts, Ivan Van Riet, Steven Raeymaeckers, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Anais Boisson

    Опубліковано 2024-01-01
    Отримати повний текст
    Стаття
    Додати у Вибране
    Збережено в:
  5. 5
    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in sol... за авторством Bart Neyns, Bart Ilsen, Jens Tijtgat, Frederik Vandenbroucke, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Steven Raemaeckers, Selma Ben Mustapha, Jens Van Loon, Lore Decoster, Mark De Ridder

    Опубліковано 2023-11-01
    Стаття
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: